CYT Overview

Key Data

  • Open $18.54
  • Day Range 18.54 - 19.65
  • 52 Week Range 16.00 - 23.10
  • Market Cap $642.87M
  • Shares Outstanding 34.03M
  • Public Float 12M
  • Beta 3.87
  • Rev. per Employee N/A
  • P/E Ratio N/A
  • EPS N/A
  • Yield N/A
  • Dividend N/A
  • Ex-Dividend Date N/A
  • Short Interest 31.74K 06/30/21
  • % of Float Shorted 0.26%
  • Average Volume 238.07K

Performance

5 Day
  • 9.23%

Recent News

  • MarketWatch
  • Dow Jones

Cyteir Therapeutics started at outperform with $40 stock price target at Wedbush

Jul. 13, 2021 at 7:49 a.m. ET by Tomi Kilgore

Cyteir Therapeutics started at overweight with $30 stock price target at J.P. Morgan

Jul. 13, 2021 at 7:15 a.m. ET by Tomi Kilgore

Solvay sales gain on FX effects; maintains outlook

Oct. 29, 2015 at 5:01 a.m. ET by Laurence Norman

Solvay boosts sales, maintains full-year outlook

Oct. 29, 2015 at 2:55 a.m. ET by Laurence Norman

Cytec Industries downgraded to sector weight from overweight at KeyBanc Capital

Aug. 13, 2015 at 8:29 a.m. ET by Tomi Kilgore

Get ready to cash in on the bottom for commodities

Jul. 29, 2015 at 9:36 a.m. ET by Barbara Kollmeyer

Belgium's Solvay to buy Cytec for $5.5 billion

Jul. 29, 2015 at 1:28 a.m. ET by Gabriele Steinhauser

Cytec Industries stock price target raised to $60 from $51 at Citigroup

Mar. 19, 2015 at 8:46 a.m. ET by Tomi Kilgore

Cytec Industries upgraded to buy from neutral at Citigroup

Mar. 19, 2015 at 8:46 a.m. ET by Tomi Kilgore

Carbon fiber is sparkling again

Oct. 4, 2013 at 7:00 a.m. ET by Ben Weiss

Cytec unveils $400 mln debt offering

Feb. 26, 2013 at 12:30 p.m. ET by Ben Fox

Can carbon make returns sparkle?

Feb. 12, 2013 at 9:29 a.m. ET by Ben Weiss

Hot stocks to watch

Jul. 20, 2012 at 8:58 a.m. ET by MarketWatch

Cytec Industries raises earnings outlook

Jul. 13, 2012 at 10:21 a.m. ET by Chelsea Stevenson

Cytec Industries up 7.8%

Jul. 13, 2012 at 9:34 a.m. ET by Steve Gelsi
Premium

Market bears hibernating?

Feb. 9, 2012 at 10:52 a.m. ET by Michael Ashbaugh

Wednesday’s biggest gaining and declining stocks

Feb. 1, 2012 at 4:46 p.m. ET by Kate Gibson

U.S. markets extend the 2012 uptrend

Jan. 10, 2012 at 11:10 a.m. ET by Michael Ashbaugh
Premium

U.S. markets extend the 2012 uptrend

Jan. 10, 2012 at 10:34 a.m. ET by Michael Ashbaugh

First Boeing 787 delivery a boost for parts makers

Sep. 26, 2011 at 12:57 p.m. ET by Christopher Hinton
  • Other News
  • Press Releases

No Headlines Available

Cyteir Therapeutics Inc.

Cyteir Therapeutics, Inc. engages in the development of novel therapeutics and deoxyribonucleic acid repair and synthetic lethal therapies. It exploits the synthetic lethality of gain-of-function DNA-damaging genes and DNA repair inhibition, resulting in selective death among cells. The company was founded by Kevin Mills and Timothy Romberger in June 2012 and is headquartered in Lexington, MA.